中国临床药学杂志2026，Vol.35Issue(2)：121-127,7.DOI:10.19577/j.1007-4406.2026.02.004
3种单克隆抗体治疗炎症性肠病的临床综合评价
Clinical comprehensive evaluation of three monoclonal antibodies for the treatment of inflammatory bowel disease
摘要
Abstract
AIM To carry out the comprehensive evaluation of 3 monoclonal antibodies in the treatment of inflammatory bowel disease from different dimensions,providing a basis for clinical rational drug use.METHODS According to the Guidelines for the management of comprehensive clinical evaluation of pharmaceuticals(2021 trial edition),evidence-based medicine research and quantitative data analysis were mainly used to comprehensively evaluate 6 dimensions:safety,effectiveness,economics,accessibility,innovation,suitability,and accessibility of vedolizumab,infliximab and adalimumab.RESULTS In terms of safety,the pre-market studies of adalimumab showed better performance,and the post-market studies of vedolizumab showed milder adverse reactions.In terms of effectiveness,infliximab was more suitable for the induction period of Crohn's disease and ulcerative colitis.Vedolizumab was more suitable for the treatment of stable ulcerative colitis and for ulcerative colitis after the failure of infliximab treatment.Adalimumab was more suitable for the treatment of Crohn's disease after the failure of infliximab treatment.In terms of cost-effectiveness,there was a significant difference in the results from different countries.Vedolizumab had a better performance in terms of innovation.In terms of suitability,adalimumab had more advantages.In terms of accessibility,the price levels of all three drugs in our country were below international standards.The availability of infliximab was more advantageous,while the affordability of adalimumab and vedolizumab was better for urban residents.CONCLUSION Each of the 3 monoclonal antibodies has its advantages in treating inflammatory bowel disease.A comparative evaluation of their effectiveness and cost-effectiveness in the Chinese population is necessary to inform clinical practice and assist medical insurance departments in making relevant decisions regarding rational drug use.关键词
维得利珠单抗/英夫利西单抗/阿达木单抗/炎症性肠病/临床综合评价Key words
vedolizumab/infiximab/adalimumab/inflammatory bowel disease/clinical comprehensive evaluation分类
医药卫生引用本文复制引用
王晓丽,郑盈盈,刘洋,王宪英..3种单克隆抗体治疗炎症性肠病的临床综合评价[J].中国临床药学杂志,2026,35(2):121-127,7.基金项目
河北省药学会"晴冀药学"医院药学专项科研项目(编号2022-Hbsyxhqjyxms21) （编号2022-Hbsyxhqjyxms21）
